ArticleFrontiers in physiology2026
Integrating the lymphocyte-albumin score into prognostic stratification of nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence indicates that the lymphocyte-albumin (LA) score, a novel biomarker that reflects systemic inflammation and nutritional status, has a strong connection with survival outcomes in a range of tumors; though its prognostic relevance in nasopharyngeal carcinoma (NPC) has not been extensively studied. The aim of this study is to explore the relationship between the LA score and survival outcomes in NPC and to establish a predictive model accordingly. Methods: This single-center retrospective study included 861 non-metastatic NPC patients who were treated with concurrent chemoradiotherapy (CCRT) between January 2010 and December 2014.Clinicopathological data, including the LA score, were collected for analysis. The optimal cutoff value for the LA score was calculated using maximally selected rank statistics. Both univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors. Additionally, a nomogram incorporating the LA score and other significant variables was developed to predict overall survival (OS). Results: Patients with elevated LA scores (>70.56) demonstrated significantly improved OS compared to those with lower scores (≤70.56) (HR = 0.572, 95% CI: 0.424-0.771, P<0.001). The multivariate analysis revealed that the LA score, along with age, T stage, N stage, and BMI, served as independent prognostic factors for OS. During a median follow-up of 123.2 months, 174 deaths were recorded. The nomogram incorporating these variables demonstrated moderate discriminative ability (C-index = 0.671, 95% CI: 0.631-0.710) and showed modest improvement over the conventional TNM staging system. Conclusion: This study is the first to highlight the prognostic relevance of the LA score in NPC patients undergoing CCRT. The LA score, being a straightforward and readily available biomarker, can complement anatomical staging for better risk stratification and personalized treatment strategies in this challenging malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.